

## Literatura ACTA MEDICINAE 11–13/2022 Onkologie | Hematoonkologie | Hematologie

- 3 [ASCO 2022 a imunoterapie karcinomu plic](#)  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 3 [Cílená léčba nemalobuněčného karcinomu plic v České republice](#)  
prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC, FN Brno a LF MU, Brno
- 4 [Pokročilý endometriální adenokarcinom a imunoterapie](#)  
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK v Plzni
- 4 [Tucatinib v léčbě metastatického HER2 pozitivního karcinomu prsu](#)  
MUDr. Miloš Holánek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 4 [Imunoterapie v léčbě nádorů močového měchýře](#)  
doc. MUDr. Alexandr Poprach, Ph. D. | doc. MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno a Lékařská fakulta Masarykovy univerzity, Brno
- 4 [Podpůrná léčba v onkologii – několik zajímavých témat](#)  
prof. MUDr. Samuel Vokurka, Ph.D. Onkologická a radioterapeutická klinika, Univerzita Karlova, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň
- 5 [Podpůrná léčba v onkologii – několik zajímavých témat – komentář k článku](#)  
Mgr. et MUDr. Petra Holečková, Ph.D., MBA Ústav radiační onkologie, Fakultní nemocnice Bulovka a 1. LF UK a IPVZ, Praha
- 5 [Nemetastatický kastročně rezistentní karcinom prostaty](#)  
MUDr. Jana Katolická, Ph.D. | MUDr. Simona Rotnágllová Onkologicko-chirurgické oddělení FN u svaté Anny v Brně
- 6 [Metamizol a jeho místo v léčbě onkologické bolesti](#)  
MUDr. Pavlína Nosková, Ph.D. KARIM VFN a 1. LF UK, Praha
- 6 [Účinnost kombinované imunoterapie u pokročilého a metastatického melanomu ve studii CheckMate 067: 7,5letá data](#)  
MUDr. Radmila Lemstrová, Ph.D. Onkologická klinika FN Olomouc a LF Univerzity Palackého, Olomouc
- 6 [Nežádoucí účinky imunoterapie v léčbě metastatického renálního karcinomu](#)  
doc. MUDr. Radek Lakomý, Ph.D. | doc. MUDr. Alexandr Poprach, Ph.D. | MUDr. Jiří Navrátil, Ph.D.  
Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MUNI, Brno
- 6 [Histopatologická klasifikace nádorů ledvin z pohledu urologa](#)  
MUDr. Jiří Kolář | MUDr. Adriana Bartoš Veselá Urologická klinika LF UK a FN Plzeň  
prof. MUDr. Ondřej Hes, Ph.D. | doc. MUDr. Kristýna Pivovarčíková, Ph.D. Šiklův ústav patologie LF UK a FN Plzeň  
prof. MUDr. Milan Hora, Ph.D. Urologická klinika LF UK a FN Plzeň
- 7 [Léčba BRAF<sup>V600E</sup> mutovaného metastatického kolorektálního karcinomu](#)  
MUDr. Eugen Kubala Onkologická klinika 1 LF UK a Fakultní Thomayerovy nemocnice, Praha
- 7 [Dlouhodobá léčba lenvatinibem u pacienta s papilárním karcinomem štítné žlázy – kazuistika](#)  
MUDr. Hana Švébišová, Ph.D. Onkologická klinika FN Olomouc a LF UP, Olomouc
- 7 [\(R\)evoluce v léčebných schématech difuzního velkobuněčného B lymfomu?](#)  
MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 8 [Primární lymfom centrální nervové soustavy](#)  
MUDr. Heidi Móciková, Ph.D. Hematologická klinika FNKV a 3. LF UK, Praha
- 8 [Léčba starších nemocných s Hodgkinovým lymfomem – rok 2022](#)  
MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice a Lékařská fakulta UK, Hradec Králové  
MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, Fakultní nemocnice Královské Vinohrady a 3. LF UK, Praha
- 9 [Současná terapie akutní lymfoblastické leukemie u dětí](#)  
doc. MUDr. Lucie Šrámková, Ph.D. Klinika dětské hematologie a onkologie, 2. LF UK a FN v Motole, Praha
- 10 [Chronická myeloidní leukemie – od poznání patogeneze k cílené léčbě onemocnění](#)  
doc. MUDr. Daniela Žáčková, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- 10 **Asciminib – tyrosinkinázový inhibitor s novým mechanismem účinku v léčbě chronické myeloidní leukemie – shrnutí aktuálních poznatků**  
MUDr. Lukáš Stejskal | MUDr. David Buffa Klinika hematookologie, FN Ostrava a LF Ostravské univerzity, Ostrava-Poruba  
MUDr. Zdeněk Kořístek, Ph.D. | prof. MUDr. Roman Hájek, CSc. Klinika hematookologie, FN Ostrava, Klinika hematookologie, LF Ostravské univerzity, Ostrava-Poruba
- 11 **Možnosti současné farmakologické léčby hemofilie – přehledový článek**  
doc. MUDr. Zuzana Čermáková, Ph.D. | MUDr. Radomíra Hrdličková | MUDr. Šárka Blahutová  
Krevní centrum FN a LF Ostravské univerzity, Ostrava
- 11 **Současné možnosti léčby hluboké žilní trombózy v onkologii, budoucí možné výhledy**  
doc. MUDr. Jana Hirmerová, Ph.D. II. interní klinika LF UK a FN Plzeň

# ASCO 2022 a imunoterapie karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 **Provencio-Pulla, M. – Spicer, J. – Taube, J. M., et al.:** Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, LBA8511 Poster Discussion Session.
- 2 **O'Brien, M. E. R. – Paz-Ares, L. – Jha, N., et al.:** EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, 8512 Poster Discussion Session.
- 3 **Jabbour, S. K. – Houghton, B. – Robinson, A. G., et al.:** Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected

- stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, TPS8597 Poster Session.
- 4 **Reck, M. – Lee, K. H. – Frost, N., et al.:** Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, 8508 Poster Discussion Session.
- 5 **Paz-Ares, L. G. – Ciuleanu, T. E. – Cobo-Dols, M., et al.:** First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, LBA9026 Poster Session.
- 6 **Garassino, M. Ch. – Felip, E. – Awad, M. M., et al.:** A randomized,

- double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non-small cell lung cancer (NSCLC): KeyVibe-007. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, TPS9160 Poster Session.
- 7 **Sands, J. – Reck, M. – Navarro, A., et al.:** KeyVibe-008: randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive stage small cell lung cancer. Prezentováno na: 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA, 3.–7. 6. 2022, TPS8606 Poster Session.
- 8 **Paz-Ares, L. G. – O'Brien, M. E. R. – Mauer, M., et al.:** VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. *Ann Oncol*, 2022, 33, s. 451–453.

## Cílená léčba nemalobuněčného karcinomu plic v České republice

prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC, FN Brno a LF MU, Brno

- 1 [www.svod.cz](http://www.svod.cz)
- 2 Národní onkologický registr – ÚZIS ČR
- 3 **Skříčková, J., et al.:** Karcinom plic. *Časopis lékařů českých*, 2018, 157, s. 226–236.
- 4 **Kadlec, B.:** Postavení imunoterapie v léčbě nemalobuněčného karcinomu plic. In: Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Praha, Maxdorf, 2017, s. 297–311.
- 5 Skříčková, J. – Petr, D.: Cílená biologická léčba nemalobuněčného karcinomu plic. *Onkologická revue*, 2019, 6, s. 25–35.
- 6 Dostupné z: <http://www.patologie.info/soubory/all/NGS.pdf>, vyhledáno 28. 7. 2022.
- 7 **Vašíková, A.:** Principy biologické léčby karcinomu plic. In: Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Praha, Maxdorf, 2017, s. 162–175.
- 8 **Mok, T. S. – Wu, Y. L. – Thongprasert, S., et al.:** Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*, 2009, 361, s. 947–957.
- 9 **Douillard, J. Y. – Ostoros, G. M. – Cobo, M., et al.:** First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. *Br J Cancer*, 2014, 110, s. 55–62.
- 10 Modrá kniha České onkologické společnosti, 28. aktuální vydání. Masarykův onkologický ústav, Brno, 2022. Linkos. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 28. 7. 2022.
- 11 **Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.:** Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- 12 **Rosell, R. – Carcereny, E. – Gervais, R., et al.:** Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 13 **Rosell, R. – Dafni, U. – Felip, E., et al.:** Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med*, 2017, 5, s. 435–444.
- 14 **Seto, T. – Kato, T. – Nishio, M., et al.:** Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 2014, 15, s. 1236–1244.
- 15 **Nagawa, K. – Garon, E. B. – Seto, T., et al.:** RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). *Lancet Oncol*, 2019, 20, s. 1655–1669.
- 16 **Saito, H. – Fukuhara, T. – Furuya, N., et al.:** Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 625–635.
- 17 **Yang, J. C. H. – Schuler, M. H. – Yamamoto, N., et al.:** LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, suppl. 18, doi: 10.1200/jco.2012.30.18\_suppl. lba7500.
- 18 **Wu, Y. L. – Zhou, C. – Hu, C. P., et al.:** Afatinib versus cisplatin plus

- gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 213–222.
- 19 **Soria, J. Ch. – Felip, E. – Cobo, M., et al.:** Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*, 2015, 16, s. 897.
- 20 **Wu, Y. L. – Cheng, Y. – Zhou, X., et al.:** Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1454–1466.
- 21 **Soria, J. Ch. – Ohe, Y. – Vansteenkiste, J., et al.:** Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125.
- 22 **Ramalingam, S. S. – Gray, J. E. – Ohe, Y., et al.:** 567 – Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. *Ann Oncol*, 2019, 30, suppl. 5, s. v914–v915.
- 23 **Mok, T. S. – Wu, Y. L. – Ahn, M. J., et al.:** Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *Engl J Med*, 2017, 376, s. 629–640.
- 24 **Herbst, R. S. – Tsuboi, M. – John, T., et al.:** Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. *J Clin Oncol*, 38, suppl. 18, doi: 10.1200/JCO.2020.38.18\_suppl.BA5.
- 25 **Soda, M. – Choi, Y. L. – Enomoto, M., et al.:** Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 26 **Wong, D. W. S. – Leung, E. L. H. – So, K. K. T., et al.:** The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115, s. 1723–1733.
- 27 **Shaw, A. T. – Kim, D. W. – Nakagawa, K., et al.:** Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). *Ann Oncol*, 2012, 23, suppl. 9, s. 21.
- 28 **Mok, T. – Kim, D. W. – Wu, Y. L., et al.:** PROFILE 1014 Investigators: First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.
- 29 **De Castro, J. – Novello, S. – Mazieres, J., et al.:** 1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. *Ann Oncol*, 2017, 28, suppl. 5, doi: 10.1093/annonc/mdx380.048.
- 30 **Peters, S. – Camidge, D. R. – Shaw, A. T., et al.:** Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *Engl J Med*, 2017, 377, s. 829–838.
- 31 **Scagliotti, G. – Kim, T. M. – Crinò, L., et al.:** Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study. 2016, doi:10.1093/annonc/mdw435.41.
- 32 **Shaw, A. T. – Kim, T. M. – Crinò, L., et al.:** Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 874–886.
- 33 **Kim, D. W. – Tiseo, M. – Ahn, M. J., et al.:** Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive

- non-small-cell lung cancer: a randomized, multicenter phase II trial. *J Clin Oncol*, 2017, 35, s. 2490–2498.
- 34 **Camidge, D. R. – Kim, H. R. – Ahn, M. J., et al.:** Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol*, 2020, 38, s. 3592.
- 35 **Horn, L. – Wang, Z. – Wu, G., et al.:** Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. *JAMA Oncol*, 2021, 7, s. 1617–1625.
- 36 **Shaw, A. T. – Felip, E. – Bauer, T. M., et al.:** Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol*, 2017, 18, s. 1590–1599.
- 37 **Solomon, B. – Bauer, T. M. – De Marinis, F., et al.:** LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study. *Ann Oncol*, 2020, 31, s. S1180–S1181.
- 38 **Drilon, A. – Siena, S. – Dziadziuszko, R., et al.:** Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. *Lancet Oncol*, 2020, 21, s. 261–270.
- 39 Xalkori SPC, [www.suk.cz](http://www.suk.cz).
- 40 **Planchard, D. – Smit, E. F. – Groen, H. J., et al.:** Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 1307–1316.
- 41 **Drilon, A. – Kummur, S. – Moreno, V., et al.:** Activity of larotrectinib in TRK fusion lung cancer. *Ann Oncol*, 2019, 30, s. ii48–ii49.
- 42 **Gainor, J. F. – Curigliano, G. – Kim, D. W.:** Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol*, 2021, 22, s. 959–969.
- 43 **Drilon, A. – Oxnard, G. R. – Tan, D. S., et al.:** Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. *Engl J Med*, 2020, 383, s. 813–824.
- 44 **Li, B. – Skoulidis, F. – Falchook, G., et al.:** PS01.07 Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the codebreak 100 primary analysis. *J Thor Oncol*, 2021, 16, s. S61.
- 45 **Reck, M. – Kaiser, R. – Mellemgaard, A., et al.:** Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155.
- 46 **Kadlec, B.:** Úloha bevacizumabu v léčbě nemalobuněčného karcinomu plic. *Farmakoterapie*, 2017, 13, s. 30–34.
- 47 **Sandler, A. – Yi, J. – Dahlberg, S., et al.:** Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. *J Thor Oncol*, 2010, 5, s. 1416–1423.
- 48 **Lopez-Chavez, A. – Young, T. – Fages, S., et al.:** Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. *J Thor Oncol*, 2012, 7, s. 1707–1712.
- 49 **Reck, M. – von Pawel, J. – Zatloukal, P., et al.:** Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 1227–1234.
- 50 **Barlesi, F. – De Castro, J. – Dvornichenko, V., et al.:** AVAPERL (MO22089): Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (Bev) or Bev+

pemetrexed (Pern) after first-line (1L) Bevacizumab (Cis)-Pemetrexed (Tx). *Eur J Cancer*, 2011, 47, s. 16 (suppl 2; abstrakt 34LBA).

51 **Crinó, L. – Dansin, E. – Garrido, P., et al.**: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAIL, MO19390): a phase 4 study. *Lancet Oncol*, 2010, 11, s. 733–740.

52 **Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.**: Ramucicrumab plus

docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673.

53 **Li, T. – King, H.-J., Mack, D. C., et al.**: Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. *J Clin Oncol*, 2013, 31, s. 1039–1049.

54 **Kris, M. – Johnson, B. E. – Berry, L. D., et al.**: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*, 2014, 311, s. 1998–2006.

55 American Cancer Society. Dostupné z: <http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf>, vyhledáno 29. 7. 2022.

## Pokročilý endometriální adenokarcinom a imunoterapie

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK v Plzni

1 **Makker, V. – Colombo, N. – Herráez, A. C., et al.**: Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*, 2022, 386, s. 437–448.

2 **Oaknin, A. – Pothuri, B. – Gilbert, L., et al.**: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. *J Clin Oncol*, 2022, 40, suppl. 16, s. 5509, doi:10.1200/JCO.2022.40.16\_suppl.5509.

3 NCCN guidelines 1.2022 endometrial cancer; [www.nccn.org](http://www.nccn.org).

4 **Makker, V., et al.**: Study 309/KEYNOTE-775. Prezentováno na 2021 SGO Virtual Annual Meeting on Women's Cancer; 19.–26. 3. 2021.

5 **Luchini, C., et al.**: ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. *Ann Oncol*, 2019, 30, s. 1232–1243.

6 **Le, D. T., et al.**: PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*, 2015, 372, s. 2509–2520.

7 **Dudley, J. C., et al.**: Microsatellite instability as a biomarker for PD-1 blockade. *Clin Cancer Res*, 2016, 22, s. 813–820.

8 **Howitt, B. E., et al.**: Association of polymerase e-mutated and microsatellite-Instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. *JAMA Oncol*, 2015, 1, s. 1319–1323.

9 SPC Jemperli, [www.sukl.cz](http://www.sukl.cz).

## Tucatinib v léčbě metastatického HER2 pozitivního karcinomu prsu

MUDr. Miloš Holánek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

1 **Murthy, R. K. – Loi, S. – Okines, A., et al.**: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.

2 **Gennari, A. – André, F. – Barrios, C. H., et al.**: ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann Oncology*, 2021, doi: <https://doi.org/10.1016/j.annonc.2021.09.019>.

3 Modrá kniha České onkologické společnosti. Masarykův onkologický ústav Brno, 2022. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 23. 8. 2022.

## Imunoterapie v léčbě nádorů močového měchýře

doc. MUDr. Alexandr Poprach, Ph. D. | doc. MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno a Lékařská fakulta Masarykovy univerzity, Brno

1 **Dušek, L. – Mužík, J. – Kubásek, M., et al.**: Epidemiologie zhoubných nádorů v České republice. Multimediální podpora výuky klinických a zdravotnických oborů: Portál Lékařské fakulty Masarykovy univerzity. Dostupné z: <https://portal.med.muni.cz/clanek-583-epidemiologie-zhoubnych-nadoru-v-ceske-republice.html>, vyhledáno 28. 6. 2022.

2 **Powles, T. – Kockx, M. – Rodriguez-Vida, A., et al.**: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nat Med*, 2019, 25, s. 1706–1714.

3 **Bandini, M. – Gibb, E. A. – Gallina, A., et al.**: Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. *Ann Oncol*, 2020, 31, s. 1755–1763.

4 **Bajorin, D. F. – Witjes, J. A. – Gschwend, J. E., et al.**: Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *N Engl J Med*, 2021, 384, s. 2102–2114.

5 **Powles, T. – Sridhar, S. S. – Loriot, Y., et al.**: Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. *Nat Med*, 2021, 27, s. 2200–2211.

6 **O'Donnell, P. H. – Balar, A. V. – Vuky, J., et al.**: First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. *J Clin Oncol*, 2021, 39, suppl. 15, s. 4508–4508.

7 **Bellmunt, J. – Necchi, A. – De Wit, R., et al.**: Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. *J Clin Oncol*, 2021, 39, suppl. 15, s. 4532–4532.

8 **Siefker-Radtke, A. O. – Baron, A. D. – Necchi, A., et al.**: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275. *J Clin Oncol*, 2019, 37, suppl. 15, s. 4524–4524.

*Další literatura u autorů.*

## Podpurná léčba v onkologii – několik zajímavých témat

prof. MUDr. Samuel Vokurka, Ph.D. Onkologická a radioterapeutická klinika, Univerzita Karlova, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň

1 Dostupné z: [www.linkos.cz/slovnicek/podpurna-lecba/](http://www.linkos.cz/slovnicek/podpurna-lecba/), vyhledáno 23. 6. 2022.

2 Dostupné z: [www.mascc.org/about-mascc](http://www.mascc.org/about-mascc), vyhledáno 23. 6. 2022.

3 Dostupné z: [www.linkos.cz/ceska-onkologicka-spolecnost-cls-jep/organizace-cos/odborne-sekce-cos/sekce-podpurne-lecby/](http://www.linkos.cz/ceska-onkologicka-spolecnost-cls-jep/organizace-cos/odborne-sekce-cos/sekce-podpurne-lecby/), vyhledáno 23. 6. 2022.

4 **Ludwig, H., et al.**: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. *Eur J Cancer*, 2004, 40, s. 2293–2306.

5 **Fein, D. A., et al.**: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. *J Clin Oncol*, 1995, 13, s. 2077–2083.

6 **Crawford, J., et al.**: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. *Cancer*, 2002, 95, s. 888–895.

7 **Glaspay, J., et al.**: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer*, 2010, 102, s. 301–315.

8 **Aapro, M., et al.**: Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. *Ann Oncol*, 2015, 26, s. 688–695.

9 **Kerkhofs, L., et al.**: Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. *Future Oncol*, 2012, 8, s. 751–756.

10 **Aapro, M., et al.**: Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*, 2018, 29, suppl. 4, s. iv96–iv110.

11 **Bohlius, J., et al.**: Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH Clinical Practice Guideline Update. *J Clin Oncol*, 2019, 37, s. 1336–1351.

12 NCCN Guidelines – Hematopoietic Growth Factors, version 4.2021. [www.nccn.org](http://www.nccn.org).

13 **Kiss, I., et al.**: Doporučení pro léčbu hematologických toxicit. *Modrá kniha České onkologické společnosti*. Vydání 28, Brno 2022, Masarykův onkologický ústav.

14 **Auerbach, M., et al.**: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol*, 2004, 22, s. 1301–1307.

15 **Vokurka, S.**: Význam a rizika růstových faktorů erytropoézy (ESA). *Podpurná léčba*, 2021, 3, s. 9–11.

16 **Pospíšilová, D., et al.**: Význam stanovení hladiny hepcidinu v diagnostice vybraných typů anemií v dětském věku. *Transfuzie Hematol Dnes*, 2012, 18, s. 58–65.

17 **Henry, D. H., et al.**: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. *Oncologist*, 2007, 12, s. 231–242.

18 European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines 2013; dostupné z: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Press\\_release/2013/06/WC500144874.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf), vyhledáno 23. 6. 2022.

19 **Lyman, G. H., et al.**: The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. *Ann Oncol*, 2013, 24, s. 2475–2484.

20 Dostupné z: [www.linkos.cz/lekar-a-multidisciplinari-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/24-31-doporuceni-pro-lecibu-hematologickych-toxicit/](http://www.linkos.cz/lekar-a-multidisciplinari-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/24-31-doporuceni-pro-lecibu-hematologickych-toxicit/), vyhledáno 23. 6. 2022.

21 **Klastersky, J., et al.**: Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol*, 2016, 27, suppl. 5, s. v111–v118.

22 **Smith, T. J., et al.**: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 2015, 33, s. 3199–3212.

23 **Aapro, M., et al.**: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur J Cancer*, 2011, 47, s. 8–32.

24 **Kurbacher, C. M., et al.**: Prophylaxis of chemotherapy-induced neutropenia with lippegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR. *ESMO congress*, 7.–11. 10. 2016, 1457P.

25 **Vokurka, S.**: Zajímavá poznámka: lippeg/peg-filgrastim v praxi. *Podpurná léčba*, 2022, 1, s. 34.

26 **Vokurka, S.**: Pegfilgrastim, lippegfilgrastim, febrilní neutropenie, udržení dávkové intenzity chemoterapie a k tomu navíc COVID-19. *Podpurná léčba*, 2020, 2, s. 3–6.

27 **Teplý, B. A. – Lipsón, E. J.**: Identification and management of toxicities from immune checkpoint-blocking drugs. *Oncology*, 2014, 28, suppl.

- 3, s. 30–38.
- 28 **Khoja, L., et al.**: Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. *Oncol Lett*, 2016, 11, s. 1581–1585.
- 29 **Pillai, R. N., et al.**: Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. *Cancer*, 2018, 124, s. 271–277.
- 30 **Postow, M., et al.**: Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*, 2018, 378, s. 158–168.
- 31 Injury, poisoning and procedural complications. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0, November 27, 2017, U.S. Department of Health and Human Services, <https://ctep.cancer.gov>.
- 32 **Haanen, J. B. A. G., et al.**: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv119–iv142.
- 33 **Champrat, S., et al.**: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol*, 2016, 27, s. 559–574.
- 34 **Osorio, J. C., et al.**: Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. *Ann Oncol*, 2017, 28, s. 583–589.
- 35 **Vokurka, S.**: Hlavní pilíře bezpečné imunoterapie. *Podpůrná léčba*, 2021, 2, s. 5–8.
- 36 **Vokurka, S. – Maňásek, V., et al.**: Extravazace (paravazace) cytostatik – doporučení pro standardní péči v rámci České republiky ze spolupráce Sekce podpůrné léčby České onkologické společnosti ČLS JEP, Onkologické sekce České asociace sester a Společnosti pro porty a permanentní katétry. *Klin Onkol*, 2019, 32, s. 463–468.
- 37 **Vokurka, S., et al.**: Extravazace (paravazace) cytostatik – aktualizované doporučení (2020) pro standardní péči v rámci České republiky ze spolupráce Sekce podpůrné léčby České onkologické společnosti ČLS JEP, České hematologické společnosti ČLS JEP, Onkologické sekce České asociace sester a Společnosti pro porty a permanentní katétry. *Klin Onkol*, 2020, 33, s. 390–395.
- 38 SPC – Hylase „Dessau“ 150 IU, prášek pro přípravu injekčního roztoku. Příloha č. 2 k rozhodnutí o převodu registrace sp.zn.sukls26323/2013.
- 39 SPC – Cyrdanax 20mg/ml inf plv 1x 500 mg, Státní ústav pro kontrolu léčiv, datum revize textu 17. 7. 2019.
- 40 **Cvek, J. – Vokurka, S. – Hajnová Fukasová, E., et al.**: Doporučení pro preventivní a léčebnou péči o kůži pacientů podstupujících radioterapii. *Klin Onkol*, 2021, 34, s. 481–487.
- 41 **Chan, R. J., et al.**: A single-blind, randomised controlled trial of StrataXRT – a silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. *Radiother Oncol*, 2019, 139, s. 72–78.
- 42 **Herst, P. M., et al.**: Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. *Radiother Oncol*, 2014, 110, s. 137–143.
- 43 **Møller, P. K., et al.**: Breast cancer patients report reduced sensitivity and pain using a barrier film during radiotherapy – A Danish intra-patient randomized multicentre study. *Technical Innovations & patient support in radiation oncology*, 2018, 7, s. 20–25.
- 44 **Žemličková, M.**: Radiační poškození kůže, prevence a léčba. *Podpůrná léčba*, 2019, 2019, s. 5–8.
- 45 **Lam, A. C. L., et al.**: Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy. v.11(6); červen 2019.
- 46 **Vokurka, S., et al.**: Postižení dutiny ústní onkologických a hematologických pacientů – doporučení pro péči ze spolupráce Sekce podpůrné léčby České onkologické společnosti ČLS JEP, České hematologické společnosti ČLS JEP, Onkologické sekce České asociace sester a Společnosti radiační onkologie, biologie a fyziky ČLS JEP. *Klin Onkol*, 2021, 34, s. 153–162.
- 47 **Madeswaran, S., et al.**: Sodium bicarbonate: A review and its uses in dentistry. *Indian J Dent Res*, 2018, 29, s. 672–677.
- 48 **Quinn, B.**: Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. *Eur J Cancer Care*, 2013, 22, s. 564–579.
- 49 **Treister, N., et al.**: Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. *Br J Cancer*, 2017, 116, s. 21–27.
- 50 **Wong, K. H., et al.**: A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. *Radiother Oncol*, 2017, 122, s. 207–211.
- 51 **Peterson, D. E., et al.**: Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*, 2015, 26, suppl. 5, s. 139–151.
- 52 **Ariyawardana, A., et al.**: Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer*, 2019, 27, s. 3985–3995.
- 53 **Rugo, H. S., et al.**: Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 654–662.
- 54 **Šípová, S., et al.**: Obecně a specifické možnosti péče o sliznicí dutiny ústní pacientů při chemoterapii, radioterapii a cílené terapii. *Klinická Onkologie*, 2019, 32, suppl. 1, abstrakt XII/294, 65.
- 55 **Hašek, J.**: Nové léčivé látky v magistraliter receptuře XIV – mikonazol a mikonazol-nitrát. *Prakt Lékáren*, 2013, 9, s. 192–195.
- 56 **Vokurka, S., et al.**: The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-L-PAM 200 mg/m<sup>2</sup> autologous hematopoietic stem cell transplantation. *Eur J Oncol Nurs*, 2011, 15, s. 508–512.
- 57 **Vokurka, S. – Hugo, J.**: *Moderní molekuly v onkologii*. Maxdorf, 2019.
- 58 SPC XGEVA 120 mg injekční roztok, 1. 2. 2021.
- 59 Státní ústav pro kontrolu léčiv, Xgeva 120 mg INJ SOL 1x1,7 ml, 1. 2. 2021.
- 60 **Lipton, A., et al.**: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. *Eur J Cancer*, 2012, 48, s. 3082–3092.
- 61 **Coleman, R., et al.**: Bone health in cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*, 2020, 31, s. 1650–1663.
- 62 **Vokurka, S.**: Denosumab u pacientů s metastatickým postižením skeletu. *Podpůrná léčba*, 2021, 1, s. 19–21.
- 63 **Hrušák, D. – Vokurka, S.**: Osteonekrózy čelistí. In: *Postižení dutiny ústní a žívného traktu onkologických pacientů*. Current Media, 2016.
- 64 **Mücke, T., et al.**: Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid – A prospective study over 6 years. *J Craniomaxillofac Surg*, 2016, 44, s. 1689–1693.
- 65 **August, Z. S.**: Hypomagnesemia. *J Am Soc Nephrol*, 1999, 10, s. 1616–1622.
- 66 **Oronsky, B., et al.**: Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. *Cancer Chemother Pharmacol*, 2017, 80, s. 895–907.
- 67 **Lam, M. – Adelstein, D. J.**: Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. *Am J Kidney Dis*, 1986, 8, s. 164–169.
- 68 **Lajer, H., et al.**: Magnesium depletion enhances cisplatin-induced nephrotoxicity. *Cancer Chemother Pharmacol*, 2005, 56, s. 537–542.
- 69 **Crona, D. J., et al.**: A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. *Oncologist*, 2017, 22, s. 609–619.
- 70 **Tatsuya, Y., et al.**: Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. *Jpn J Clin Oncol*, 2014, 44, s. 346–354.
- 71 **Saif, M. W.**: Management of hypomagnesemia in cancer patients receiving chemotherapy. *J Support Oncol*, 2008, 6, s. 243–248.
- 72 **Costa, A., et al.**: Hypomagnesemia and targeted anti-epidermal growth factor receptor (EGFR) agents. *Targ Oncol*, 2011, 6, s. 237–233.
- 73 **Chen, P., et al.**: Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. *Oncol Lett*, 2013, 5, s. 1915–1920.
- 74 **Wang, Q., et al.**: Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: A pooled analysis of 25 randomized clinical trials. *Tumour Biol*, 2015, 36, s. 3471–3482.
- 75 **Lewis, J. L.**: Hypomagnesemia. MSD Manual Professional Version. Review/revision Apr 2020, dostupné z: <https://www.msdmanuals.com/en-gb/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypomagnesemia>, vyhledáno 18. 4. 2021.
- 76 **Vokurka, S.**: Hypomagnesemie u onkologických pacientů a možnosti řešení. *Podpůrná léčba*, 2021, 2, s. 27–30.
- 77 **Osterlund, P., et al.**: Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. *Br J Cancer*, 2007, 97, s. 1028–1034.
- 78 **Lalla, R., et al.**: MASCC/ISOO Clinical Practice Guidelines for the management of mucositis secondary to cancer therapy. *Cancer*, 2014, 15, s. 1453–1461.
- 79 **Peterson, D. E., et al.**: Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*, 2015, 26, s. 139–151.
- 80 **Bossi, P., et al.**: Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol*, 2018, 29, s. 126–142.
- 81 **Vokurka, S.**: Doporučení pro využití probiotik u onkologické léčbě? *Podpůrná léčba*, 2019, 3, s. 14.

## Podpůrná léčba v onkologii – několik zajímavých témat – komentář k článku

Mgr. et MUDr. Petra Holečková, Ph.D., MBA Ústav radiační onkologie, Fakultní nemocnice Bulovka a 1. LF UK a IPVZ, Praha

- 1 **Martin, L. – Senesse, P. – Gioulbasanis, I., et al.**: Diagnostic criteria for the classification of cancer-associated weight loss. *J Clin Oncol*, 2015, 33, s. 90–99.

## Nemetastatický kastračně rezistentní karcinom prostaty

MUDr. Jana Katolická, Ph.D. | MUDr. Simona Rotnágllová Onkologicko-chirurgické oddělení FN u svaté Anny v Brně

- 1 **Scher, H. I. – Halabi, S. – Tannock, I., et al.**: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol*, 2008, 26, s. 1148–1159.
- 2 **Ryan, Ch. J. – Small, E. J.**: Role of secondary hormonal therapy in the management of recurrent prostate cancer. *Urology*, 2003, 62, suppl. 1, s. 87–94.
- 3 **Sartor, A. O. – Tangen, C. M. – Hussain, M. H., et al.**: Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426). *Cancer*, 2008, 112, s. 2393–2400.
- 4 **Smith, M. R. – Saad, F. – Coleman, R., et al.**: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. *Lancet*, 2012, 379, s. 39–46.
- 5 **Smith, M. R. – Saad, F. – Shore, N. D., et al.**: Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. *J Clin Oncol*, 2012, 30, suppl. 5, s. 6–6, DOI: 10.1200/jco.2012.30.5\_suppl.6.
- 6 **Catrinii, C. – Caffo, O. – de Giorgi, U., et al.**: Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A critical review. *Cancers*, 2022, 14, s. 1792, <https://doi.org/10.3390/cancers14071792>.
- 7 **Smith, M. R. – Saad, F. – Chowdhury, S., et al.**: Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*, 2018, 378, s. 1408–1418.
- 8 **Hussain, M. – Fizazi, K. – Saad, F., et al.**: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2018, 378, s. 2465–2474.
- 9 **Fizazi, K. – Shore, N. – Tammela, T. L., et al.**: Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2019, 380, s. 1235–1246.
- 10 **Smith, M. R. – Saad, F. – Chowdhury, S., et al.**: Apalutamide and overall survival in prostate cancer. *Eur Urol*, 2021, 79, s. 150–158.
- 11 **Sternberg, C. N. – Fizazi, K. – Saad, F., et al.**: Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2020, 382, s. 2197–2206.
- 12 **Fizazi, K. – Shore, N. – Tammela, T. L., et al.**: Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*, 2020, 383, s. 1040–1049.
- 13 **Xie, W. – Regan, M. M. – Buyse, M., et al.**: Metastasis-free survival as a strong surrogate of overall survival in localized prostate cancer. *J Clin Oncol*, 2017, 35, s. 3097–3104.
- 14 **Oudard, S. – Hadaschik, B. – Saad, F., et al.**: Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy. *Eur Urol Focus*, 2021, S2405–4569(21)00220-0.
- 15 **Shen, J. – Chowdhury, S. – Agarwal, N., et al.**: 618P – Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN. *Ann Oncol*, 2021, 32, suppl. 5, s. S656–S657.
- 16 **Tomal, B. – Hussain, M. – Penson, D., et al.**: 807 P Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. *Ann Oncol*, 2018, 29, suppl. 8, s. viii278–viii279.
- 17 **De Giorgi, U. – Hussain, M. – Shore, N., et al.**: Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. *Eur J Cancer*, 2021, 159, s. 237–246.
- 18 **Smith, M. R. – Shore, N. – Tammela, T. L., et al.**: Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. *Eur J Cancer*, 2021, 154, s. 138–146.
- 19 **Wallis, Ch. J. D.**: 2022 American Urological Association (AUA) Annual Meeting, New Orleans, LA, 13. 5. – 16. 5. 2022.

# Metamizol a jeho místo v léčbě onkologické bolesti

MUDr. Pavlína Nosková, Ph.D. KARIM VFN a 1. LF UK, Praha

- Hakl, M. – Fricová J. – Gabrhelík, T.: Metodické pokyny pro farmakoterapii akutní bolesti: Speciální část. *Bolest*. Praha, Tigris, 2016, 19, suppl. 1, s. 15–18.
- Kabelka, L. – Kozák, J. – Lejčko, J., et al.: Doporučený postup pro léčbu průlomové nádorové bolesti. *Bolest*, 2011, 14, suppl. 1, s. 1–5.
- Rychlíčková, J. – Jurečková, H.: Metamizol (dipyrone). *Klin Farmakol Farm*, 2021, 35, s. 94–98.
- Nikolova, I. – Petkova, V. – Tencheva, J., et al.: Metamizole: a review profile of a well-known „forgotten” drug part II: clinical profil. *Biotechnol A Biotechnol Eq*, 2013, 27, s. 3605–3619.
- Rozsivalová, P. – Štichauer, R. – Holická, L., et al.: Metamizol v léčbě bolesti u dětské populace. *Pediatr Praxi*, 2020, 21, s. 323–329.
- Nassini, R. – Fusi, C. – Materazzi, S., et al.: The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. *Br J Pharmacol*, 2015, 172, s. 3397–3411.
- Miljković, M. N. – Rančić, N. K. – Šimić, R. M., et al.: Metamizole: current status of the safety and efficacy. *Hospital Pharmacology*, 2018, 5, s. 694–704.
- Šimiček, M.: Oxfordská liga analgetik a terapie akutní bolesti z pohledu farmaceuta. *Prakt Lékáren*, 2014, 10, s. 166–170.
- Kršiak, M. – Doležal, T. – Lejčko, J.: Neopioidní analgetika. In: Rokyta, R. – Kršiak, M. – Kozák, J.: *Bolest*. Praha, Tigris, 2006, s. 109–120.
- Kršiak, M.: Farmakoterapie bolesti zad. *Bolest*, 2007, 10, s. 14.
- Gaertner, J. – Stamer, U. M. – Remi, C., et al.: Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. *Palliat Med*, 2017, 31, s. 26–34.
- Informační dopis – Metamizol: Riziko léky indukovaného poškození jater. SÚKL 2020. Dostupné z: <https://www.sukl.cz/leciva/informacni-dopis-metamizol-riziko-leky-indukovaneho>, vyhledáno 27. 8. 2022.
- Malsy, M. – Graf, B. – Bunscherer, A.: Effects of metamizole, MAA, and paracetamol on proliferation, apoptosis, and necrosis in the pancreatic cancer cell lines PaTu 8988 t and Panc-1. *BMC Pharmacol Toxicol*, 2017, 18, s. 77.
- Bunscherer, A. – Malsy, M. – Gruber, M. A., et al.: Acetaminophen and metamizole induce apoptosis in HT 29 and SW 480 colon carcinoma cell lines in vitro. *Anticancer Res*, 2018, 38, s. 745–751.
- Nikolova, I. – Marinov, L. – Georgieva, A., et al.: Matamizole (dipyrone)-cytotoxic and anti proliferative effects on HeLa, HT-29 and MCF-7 cancer cell lines. *Biotechnol Biotechnol Eq*, 2018, 32, s. 1327–1337.
- Zajaczkowska, R. – Kwiatkowski, K. – Pawlik, K., et al.: Metamizol relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model of neuropathic pain. *Pharmacological Reports*, 2020, 72, s. 1310–1322.
- SPC Novalgín. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0055823&tab=texts>, vyhledáno 27. 8. 2022.
- Derry, S. – Faura, C. – Edwards, J., et al.: Single-dose dipyrone for acute postoperative pain. *Cochrane Database Syst Rev*, 2013, CD003227.
- Torres, L. M. – Rodríguez, M. J. – Montero, A., et al.: Efficacy and safety of dipyrone versus tramadol in the management of pain after hysterectomy: a randomized, double-blind, multicenter study. *Reg Anesth Pain Med*, 2001, 26, s. 118–124.

# Účinnost kombinované imunoterapie u pokročilého a metastatického melanomu ve studii CheckMate 067: 7,5letá data

MUDr. Radmila Lemstrová, Ph.D. Onkologická klinika FN Olomouc a LF Univerzity Palackého, Olomouc

- Hodi, F. S. – Postow, M. A. – Chesney, J. A., et al.: Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. *J Clin Oncol*, 2015, 33, suppl. 15, s. 9004–9004.
- Larkin, J. – Chiarion-Sileni, V. – Gonzales, R., et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*, 2015, 373, s. 23–34.
- Hodi, F. S. – Chiarion-Sileni, V. – Lewis, K. D., et al.: Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. *J Clin Oncol*, 2022, 40, suppl. 16, s. 9522–9522.

# Nežádoucí účinky imunoterapie v léčbě metastatického renálního karcinomu

doc. MUDr. Radek Lakomý, Ph.D. | doc. MUDr. Alexandr Poprach, Ph.D. | MUDr. Jiří Navrátil, Ph.D.

Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MUNI, Brno

- Schneider, B. J. – Naidoo, J. – Santomasso, B. D., et al.: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. *J Clin Oncol*, 2021, 39, s. 4073–4126.
- Brahmer, J. R. – Abu-Sbeih, H. – Ascierto, P. A., et al.: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*, 2021, 9, s. e002435.
- Haanen, J. B. A. G. – Carbone, F. – Robert, C., et al.: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv119–iv142.
- Martini, D. J. – Liu, Y. – Shabto, J. M., et al.: Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. *Oncologist*, 2020, 25, s. e484–e491.
- Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- Motzer, R. J. – Rini, B. I. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 1370–1385.
- Cella, D. – Grünwald, V. – Escudier, B., et al.: Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 297–310.
- Geynisman, D. M. – Du, E. X. – Yang, X., et al.: Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. *Future Oncol*, 2022, 18, s. 1219–1234.
- Massari, F. – Mollica, V. – Rizzo, A., et al.: Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. *Expert Opin Drug Saf*, 2020, 19, s. 1329–1338.
- Champiat, S. – Lambotte, O. – Barreau, E., et al.: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. *Ann Oncol*, 2016, 27, s. 559–574.
- Rini, B. I. – Plimack, E. R. – Stus, V., et al.: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*, 2019, 380, s. 1116–1127.
- Choueiri, T. K. – Powles, T. – Buratto, M., et al.: Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*, 2021, 384, s. 829–841.
- Grünwald, V. – Voss, M. H. – Rini, B. I., et al.: Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. *Br J Cancer*, 2020, 123, s. 898–904.
- McGregor, B. – Mortazavi, A. – Cordes, L., et al.: Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. *Cancer Treat Rev*, 2022, 103, s. 102333.
- ESMO 2019, dostupné z: <https://www.linksos.cz/files/klinicka-onkologie/452/5480.pdf>, vyhledáno 17. 5. 2022.

# Histopatologická klasifikace nádorů ledvin z pohledu urologa

MUDr. Jiří Kolář | MUDr. Adriana Bartoš Veselá Urologická klinika LF UK a FN Plzeň

prof. MUDr. Ondřej Hes, Ph.D. | doc. MUDr. Kristýna Pivovaráčková, Ph.D. Šiklův ústav patologie LF UK a FN Plzeň

prof. MUDr. Milan Hora, Ph.D. Urologická klinika LF UK a FN Plzeň

- Cimadamore, A. – Cheng, L. – Scarpelli, M., et al.: Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. *Transl Androl Urol*, 2021, 10, s. 1506–1520.
- Kovacs, G. – Akhtar, M. – Beckwith, B. J., et al.: The Heidelberg classification of renal cell tumours. *J Pathol*, 1997, 183, s. 131–133.
- WHO Classification of Tumours Editorial Board. Urinary and male genital tumours Lyon (France): International Agency for Research on Cancer; 2022. Dostupné z: <https://tumourclassification.iaarc.who.int/chapters/36>, vyhledáno 14. 7. 2022.
- Kolář, J. – Pitra, T. – Pivovaráčková, K., et al.: Hereditární renální nádorové syndromy. *Ces Urol*, 2020, 24, s. 26–41.
- Moch, H. – Cubilla, A. L. – Humphrey, P. A., et al.: The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. *Eur Urol*, 2016, 70, s. 93–105.
- Feng, X. – Zhang, L. – Tu, W., et al.: Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: A SEER-based analysis. *Medicine*, 2019, 98, s. e16684.
- Ljungberg, B. – Albiges, L. – Abu-Ghanem, Y., et al.: European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*, 25. 3. 2022, S0302-2838(22)01676-1681.
- Neves, J. B. – Vanaclocha Saiz, L. – Abu-Ghanem, Y., et al.: Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. *World J Urol*, 2021, 39, s. 3823–3831.
- Hes, O. H. M. – Pitra, T. – Šedivcová, M., et al.: Nové perspektivní jednotky: nádory ledvin popsané v době po WHO histopatologické klasifikaci z roku 2016. *Ces Urol*, 2020, 3, s. 183–190.

# Léčba *BRAF*<sup>V600E</sup> mutovaného metastatického kolorektálního karcinomu

MUDr. Eugen Kubala Onkologická klinika 1 LF UK a Fakultní Thomayerovy nemocnice, Praha

- Ros, J. – Baraibar, I. – Sardo, E., et al.: BRAF, MEK and EGFR inhibition as treatment strategies in BRAF<sup>V600E</sup> metastatic colorectal cancer. *Ther Adv Med Oncol*, 2021, 13, 1758835921992974.
- Corcoran, R. B. – Ebi, H. – Turke, A. B., et al.: EGFR mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov*, 2012, 2, s. 227–235.
- Loupakis, F. – Ruzzo, A. – Cremolini, C., et al.: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer*, 2009, 101, s. 715–721.
- Clarke, C. N. – Kopetz, S.: BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. *J Gastrointest Oncol*, 2015, 6, s. 660–667.
- Ogino, S. – Brahmandam, M. – Cantor, M., et al.: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. *Mod Pathol*, 2006, 19, s. 59–68.
- Gonsalves, W. I. – Mahoney, M. R. – Sargent, D. J., et al.: Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. *J Natl Cancer Inst*, 2014, 106, dju106.
- Cantwell-Dorris, E. R. – O'Leary, J. J. – Sheils, O. M.: BRAFV600E: implications for carcinogenesis and molecular therapy. *Mol Cancer Ther*, 2011, 10, s. 385–394.
- Venderbosch, S. – Nagtegaal, I. D. – Maughan, T. S., et al.: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. *Clin Cancer Res*, 2014, 20, s. 5322–5330.
- Jones, J. C. – Renfro, L. A. – Al-Shamsi, H. O., et al.: NonV600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. *J Clin Oncol*, 2017, 35, s. 2624–2630.
- Yao, Z. – Yaeger, R. – Rodrik-Outmezguine, V. S., et al.: Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature*, 2017, 548, s. 234.
- Cremolini, C. – Loupakis, F. – Antoniotti, C., et al.: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: update of overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol*, 2015, 16, s. 1306–1315.
- Cremolini, C. – Antoniotti, C. – Rossini, D., et al.: Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*, 2020, 21, s. 497–507.
- Cremolini, C. – Antoniotti, C. – Rossini, D., et al.: Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*, 2020, 21, s. 497–507.
- Kopetz, S. – Desai, J. – Chan, E., et al.: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. *J Clin Oncol*, 2015, 33, s. 4032–4038.
- Hyman, D. M. – Puzanov, I. – Subbiah, V., et al.: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med*, 2015, 373, s. 726–736.
- Seligmann, J. F. – Fisher, D. – Smith, C. G., et al.: Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis of 2530 patients in randomised clinical trials. *Ann Oncol*, 2017, 28, s. 562–568.
- Prahallad, A. – Sun, C. – Huang, S., et al.: Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. *Nature*, 2012, 483, s. 100–103.
- Corcoran, R. B. – Ebi, H. – Turke, A. B., et al.: EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov*, 2012, 2, s. 227–235.
- Corcoran, R. B. – Andre, T. – Atreya, C. E., et al.: Combined BRAF, EGFR,

and MEK inhibition in patients with BRAF V600E-mutant colorectal cancer. *Cancer Discov*, 2018, 8, s. 428–443.

20 Van Cutsem, E. – Huijberts, S. – Grothey, A., et al.: Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON colorectal cancer study. *J Clin Oncol*, 2019, 37, s. 1460–1469.

21 Delord, J. P. – Robert, C. – Nyakas, M., et al.: Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. *Clin Cancer Res*, 2017, 23, s. 5339–5348.

22 Tabernero, J. – Van Geel, R. – Guren, T. K., et al.: Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAF mCRC). *J Clin Oncol*, 2016, 34, suppl. 15, s. 3544–3544.

23 van Geel, R. M. J. M. – Tabernero, J. – Elez, E., et al.: A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. *Cancer Discov*, 2017, 7, s. 610–619.

24 Kopetz, S. – Grothey, A. – Van Cutsem, E., et al.: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). *J Clin Oncol*, 2020, 38, suppl. abstrakt 4001.

25 Tabernero, J. – Grothey, A. – Van Cutsem, E., et al.: Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. *J Clin Oncol*, 2021, 39, s. 273–284.

26 Dummer, R. – Ascierto, P. A. – Gogas, H. J., et al.: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 1315–1327.

## Dlouhodobá léčba lenvatinibem u pacienta s papilárním karcinomem štítné žlázy – kazuistika

MUDr. Hana Švébišová, Ph.D. Onkologická klinika FN Olomouc a LF UP, Olomouc

- Newbold, K. L. – Flux, G. – Wadley, J.: Radioiodine for high risk and radioiodine refractory thyroid cancer: current concepts in management. *Clin Oncol (R Coll, Radiol)*, 2017, 29, s. 307–309.
- Dostupné z: [https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_cs.pdf), vyhledáno 5. 9. 2022.
- Masayuki, T. – Toshiro, S.: Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. *BMC Cancer*, 2018, 18, s. 698.
- Schlumberger, M. – Tahara, M. – Wirth, L. J., et al.: Lenvatinib versus placebo in radioiodine – refractory thyroid cancer. *N Engl J Med*, 2015, 372, s. 621–630.
- Porcelli, T. – Luongo, C. – Sessa, F., et al.: Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. *Endocrine*, 2021, 73, s. 358–366.

## (R)evoluce v léčebných schématech difuzního velkobuněčného B lymfomu?

MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- Coiffier, B. – Thieblemont, C. – Van Den Neste, E., et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood*, 2010, 116, s. 2040–2045.
- Alizadeh, A. A. – Eisen, M. B. – Davis, R. E., et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 2000, 403, s. 503–511.
- Hans, C. P. – Weisenburger, D. D. – Greiner, T. C., et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, 2004, 103, s. 275–282.
- Chapuy, B. – Stewart, C. – Dunford, A. J., et al.: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*, 2018, 24, s. 679–690.
- Schmitz, R. – Wright, G. W. – Huang, D. W., et al.: Genetics and pathogenesis of diffuse large B-cell lymphoma. *N Engl J Med*, 2018, 378, s. 1396–1407.
- Wright, G. W. – Huang, D. W. – Phelan, J. D., et al.: A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. *Cancer Cell*, 2020, 37, s. 551–568; e514.
- Vitolo, U. – Trněný, M. – Belada, D., et al.: Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*, 2017, 35, s. 3529–3537.
- Sehn, L. H. – Herrera, A. F. – Flowers, C. R., et al.: Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. *J Clin Oncol*, 2020, 38, s. 155–165.
- Liebers, N. – Duell, J. – Fitzgerald, D., et al.: Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. *Blood Adv*, 2021, 5, s. 2707–2716.
- Tilly, H. – Morschhauser, F. – Sehn, L. H., et al.: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 351–363.
- Hutchings, M. – Morschhauser, F. – Iacoboni, G., et al.: Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. *J Clin Oncol*, 2021, 39, s. 1959–1970.
- Locke, F. L. – Miklos, D. B. – Jacobson, C. A., et al.: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 640–654.
- Bishop, M. R. – Dickinson, M. – Purtil, D., et al.: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 629–639.
- Kamdar, M. – Solomon, S. R. – Arnason, J., et al.: Lisocabtagene marelucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*, 2022, 399, s. 2294–2308.
- Perales, M. A. – Anderson, L. D. Jr. – Jain, T., et al.: Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther*, 2022, 28, s. 546–559.
- Neelapu, S. S. – Dickinson, M. – Munoz, J., et al.: Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med*, 2022, 28, s. 735–742.
- Wang, M. – Fowler, N. – Wagner-Bartak, N., et al.: Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. *Leukemia*, 2013, 27, s. 1902–1909.
- Nowakowski, G. S. – Chiappella, A. – Gascoyne, R. D., et al.: ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. *J Clin Oncol*, 2021, 39, s. 1317–1328.
- Chamuleau, M. E. D. – Burggraaff, C. N. – Nijland, M., et al.: Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. *Haematologica*, 2020, 105, s. 2805–2812.
- Westin, J. – Nastoupil, L. J. – Fayad, L., et al.: Smart start: Final results of rituximab, lenalidomide, and ibritinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. *J Clin Oncol*, 2019, 37, suppl. 15, s. 7508–7508.
- Salles, G. – Duell, J. – Gonzalez Barca, E., et al.: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol*, 2020, 21, s. 978–988.
- Belada, D. – Kopeckova, K. – Bergua, J. M., et al.: First-MIND: a phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with

newly diagnosed DLBCL. *J Clin Oncol*, 2021, 39, suppl. 15, s. 7540–7540.

23 Vitolo, U. – Nowakowski, G. S. – Burke, J. M., et al.: ABCL-021: FRONT-MIND: A phase III, randomized, double-blind, placebo-controlled study comparing efficacy and safety of tafitamab + lenalidomide + R-CHOP vs R-CHOP alone for newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). *Clin Lymphoma, Myeloma, Leukemia*, 2021, 21, s. S376–S377.

24 Scott, D. W. – Mottok, A. – Ennishi, D., et al.: Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. *J Clin Oncol*, 2015, 33, s. 2848–2856.

25 Younes, A. – Sehn, L. H. – Johnson, P., et al.: Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin,

vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. *J Clin Oncol*, 2019, 37, s. 1285–1295.

26 Wilson, W. H. – Wright, G. W. – Huang, D. W., et al.: Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. *Cancer Cell*, 2021, 39, s. 1643–1653, e1643.

27 Davies, A. – Cummin, T. E. – Barrans, S., et al.: Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 649–662.

28 Galvez, C. – Karmali, R. – Hamadani, M., et al.: A phase I-II trial of DA-EPOCH-R plus ixazomib as frontline therapy for patients with MYC-aberrant lymphoid malignancies: the daciphor regimen. *Blood*, 2020, 136, s. 44–45.

29 Morschhauser, F. – Feugier, P. – Flinn, I. W., et al.: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. *Blood*, 2021, 137, s. 600–609.

30 Sarkozy, C. – Morschhauser, F. – Dubois, S., et al.: A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. *Clin Cancer Res*, 2020, 26, s. 3145–3153.

31 Kalakonda, N. – Maerevoet, M. – Cavallo, F., et al.: Selineor in patients with relapsed or refractory diffuse large B-cell lymphoma (SAD-AL): a single-arm, multinational, multicentre, open-label, phase 2 trial. *Lancet Haematol*, 2020, 7, s. e511–e522.

## Primární lymfom centrální nervové soustavy

MUDr. Heidi Móciková, Ph.D. Hematologická klinika FNKV a 3. LF UK, Praha

1 Kluin, P. M. – Deckert, M. – Ferry, J. A.: Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow, S. H. – Campo, E. – Harris, N. L., et al. (eds.): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research in Cancer; 2017, s. 300–302.

2 Alaggio, R. – Amador, C. – Anagnostopoulos, I., et al.: The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. *Leukemia*, 2022, 36, s. 1720–1748.

3 Mocikova, H. – Pytlík, R. – Benesova, K., et al.: Peripheral T-Cell lymphomas involving the central nervous system: a report from the Czech Lymphoma Study Group Registry. *Front Oncol*, 2022, 12, s. 874462.

4 Barajas, R. F. – Politi, L. S. – Anzalone, N., et al.: Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). *Neuro Oncol*, 2021, 23, s. 1056–1071.

5 Herhaus, P. – Lipkova, J. – Lammer, F., et al.: CXCR4-targeted PET imaging of central nervous system B-cell lymphoma. *J Nucl Med*, 2020, 61, s. 1765–1771.

6 Ferreri, A. J. M. – Calimeri, T. – Lopodote, P., et al.: MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. *Br J Haematol*, 2021, 193, s. 497–505.

7 Junyao, Y. – Huaping, D. – Xueshi, Y., et al.: High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical

trials. *Sci Rep*, 2021, 11, s. 2125.

8 Ferreri, A. J. – Cwynarski, K. – Pulczynski, E., et al.: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematol*, 2016, 3, s. e217–227.

9 Ferreri, A. J. M. – Cwynarski, K. – Pulczynski, E., et al.: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*, 2017, 4, s. e510–523.

10 Ferreri, A. J. M. – Cwynarski, K. – Pulczynski, E., et al.: Long-term efficacy, safety and neurotoxicity of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. *Leukemia*, 2022, 36, s. 1870–1878.

11 Xuefei, S. – Yuchen, W. – Ruixian, X., et al.: Non-myeloablative chemotherapy as consolidation strategy after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: a retrospective single center study in China. *Front Oncol*, 2022, 12, s. 792274.

12 Omuro, A. – Chinot, O. – Tailandier, L., et al.: Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. *Lancet Haematol*, 2015, 2, s. e251–e259.

13 Schorb, E. – Fox, C. P. – Fritsch, K., et al.: High-dose thiotepa-based

chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. *Bone Marrow Transplant*, 2017, 52, s. 1113–1119.

14 Pulczynski, E. J. – Kuitinen, O. – Erlanson, M., et al.: Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. *Haematologica*, 2015, 100, s. 534–540.

15 Soussain, C. – Choquet, S. – Blonski, M., et al.: Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. *Eur J Cancer*, 2019, 117, s. 121–130.

16 Grommes, C. – Tang, S. S. – Wolfe, J., et al.: Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. *Blood*, 2019, 133, s. 436–445.

17 Rubenstein, J. L. – Geng, H. – Fraser, E. J., et al.: Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. *Blood Adv*, 2018, 2, s. 1595–1607.

18 Tun, H. W. – Johnston, P. B. – DeAngelis, L. M., et al.: Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. *Blood*, 2018, 132, s. 2240–2248.

19 Frigault, M. J. – Dietrich, J. – Martinez-Lage, M., et al.: Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. *Blood*, 2019, 134, s. 860–866.

## Léčba starších nemocných s Hodgkinovým lymfomem – rok 2022

MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice a Lékařská fakulta UK, Hradec Králové

MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, Fakultní nemocnice Královské Vinohrady a 3. LF UK, Praha

1 ÚZIS ČR, www.uzis.cz.

2 Evens, A. M. – Sweetenham, J. W. – Horning, S. J.: Hodgkin lymphoma in older patients: an uncommon disease in need of study. *Oncology*, 2008, 22, s. 1369–1379.

3 Sýkorová, A. – Mocikova, H. – Lukasova, M., et al.: Outcome of elderly patients with classical Hodgkin's lymphoma. *Leuk Res*, 2020, 90, s. 106311.

4 Engert, A., et al.: Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. *J Clin Oncol*, 2005, 23, s. 5052–5060.

5 Landgren, O., et al.: Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. *Haematologica*, 2003, 88, s. 438–444.

6 Ballova, V., et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). *Ann Oncol*, 2005, 16, s. 124–131.

7 Evens, A. M., et al.: The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol*, 2013, 161, s. 76–86.

8 Pulte, D. – Jansen, L. – Gondos, A., et al.: Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. *Br J Haematol*, 2014, 164, s. 851–857.

9 Evens, A. M., et al.: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. *Blood*, 2012, 119, s. 692–695.

10 Stamatopoulos, A. Brice, P. – Bouabdallah, R., et al.: Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest lifting the use of bleomycin in the elderly. *Br J Haematol*, 2015, 170, s. 179–184.

11 Specht, L. – Nissen, N. I.: Hodgkin's disease and age. *Eur J Haematol*,

1989, 43, s. 127–135.

12 Greaves, P., et al.: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. *J Clin Oncol*, 2013, 31, s. 256–262.

13 Kelley, T. W. – Pohlman, B. – Elson, P., et al.: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. *Am J Clin Pathol*, 2007, 128, s. 958–965.

14 Wildiers, H. – Heeren, P. – Puts, M., et al.: International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol*, 2014, 32, s. 2595–2603.

15 Hurria, A., et al.: Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. *J Clin Oncol*, 2011, 29, s. 1290–1296.

16 Puts, M. T. E., et al.: An update on a systematic review of the use of geriatric assessment for older adults in oncology. *Ann Oncol*, 2014, 25, s. 307–315.

17 Ballova, V., et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol*, 2005, 16, s. 124–131.

18 Halbsguth, T. V., et al.: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). *Blood*, 2010, 116, s. 2026–2032.

19 Johnson, P., et al.: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. *N Engl J Med*, 2016, 374, s. 2419–2429.

20 Gallamini, A., et al.: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. *J Clin Oncol*, 2007, 25, s. 3746–3752.

21 Sieber, M. – Engert, A. – Diehl, V.: Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. *Ann Oncol*, 2000, 11, suppl. 1, s. 81–85.

22 Hasenclever, D. – Diehl, V.: A prognostic core for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med*, 1998, 339, s. 1506–1514.

23 Cuccaro, A., et al.: Prognostic factors in Hodgkin lymphoma. *Mediterr J Hematol Infect Dis*, 2014, 6, s. e2014053.

24 Cheson, B. D.: Staging and response assessment in lymphomas: the new Lugano classification. *Chin Clin Oncol*, 2015, 4, s. 5.

25 Barrington, S. F., et al.: Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol*, 2014, 32, s. 3048–3058.

26 Lynch, R. C., et al.: Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. *Blood*, 2021, 138, s. 233.

27 Di Trani, M. – Rizzo, E. – Locatelli, S., et al.: Longitudinal assessment of circulating tumor mutational burden using a next-generation sequencing cancer gene panel: a potential biomarker of response to programmed cell death 1 (PD-1) blockade in patients with relapsed/refractory classical Hodgkin lymphoma. *Blood*, 2019, 134, suppl. 1, s. 131.

28 Rossi, C., et al.: High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline. *Haematologica*, 2022, doi:10.3324/haematol.2021.280004.

29 Procházka, V., et al.: Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. *Biol Blood Marrow Transplant*, 2018, 24, s. 64–70.

30 Spina, V., et al.: Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. *Blood*, 2018, 131, s. 2413–2425.

31 Cirillo, M. – Borchmann, S.: An update on disease biomarkers for



- Hodgkin lymphoma. *Expert Rev Hematol*, 2020, 13, s. 481–488.
- 32 Camus, V., et al.: Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. *Haematologica*, 2016, 101, s. 1094–1101.
  - 33 Katz, S., Ford, A. B., Moskowitz, R., et al.: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. *J Am Med Association*, 1963, 185, s. 914–919.
  - 34 Lawton, M. P., Brody, E. M.: Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*, 1969, 9, s. 179–186.
  - 35 Charlson, M., Szatrowski, T. P., Peterson, J., et al.: Validation of a combined comorbidity index. *J Clin Epidemiol*, 1994, 47, s. 1245–1251.
  - 36 Carter, J., David, K. A., Kritharis, A., et al.: Current treatment options for older patients with Hodgkin lymphoma. *Curr Treat Options Oncol*, 2020, 21, s. 42.
  - 37 Evens, A. M., et al.: Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. *J Clin Oncol*, 2018, 36, s. 3015–3022.
  - 38 Erdkamp, F. L., Breed, W. P., Bosch, L. J., et al.: Hodgkin disease in the elderly. A registry-based analysis. *Cancer*, 1992, 70, s. 830–834.
  - 39 Weekes, C. D., et al.: Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. *J Clin Oncol*, 2002, 20, s. 1087–1093.
  - 40 Levis, A., et al.: Probability of cure in elderly Hodgkin's disease patients. *Haematologica*, 1994, 79, s. 46–54.
  - 41 Böll, B., et al.: Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. *J Clin Oncol*, 2013, 31, s. 4431–4437.
  - 42 Böll, B., et al.: Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSg) HD10 and HD13 trials. *Blood*, 2016, 127, s. 2189–2192.
  - 43 Böll, B., et al.: ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol*, 2013, 31, s. 1522–1529.
  - 44 Azambuja, E., Fleck, J. F., Batista, R. G., Menna Barreto, S. S.: Bleomycin lung toxicity: who are the patients with increased risk? *Pulm Pharmacol Ther*, 2005, 18, s. 363–366.
  - 45 Proctor, S. J., et al.: Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. *Blood*, 2012, 119, s. 6005–6015.
  - 46 Behringer, K., et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSg HD13): an open-label, randomised, non-inferiority trial. *Lancet*, 2015, 385, s. 1418–1427.
  - 47 Follows, G. A., et al.: Guideline for the first-line management of Classical Hodgkin Lymphoma – A British Society for Haematology guideline. *Br J Haematol*, 2022, 197, s. 558–572.
  - 48 Forero-Torres, A., et al.: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. *Blood*, 2015, 126, s. 2798–2804.
  - 49 Friedberg, J. W., et al.: Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥ 60 years with HL. *Blood*, 2017, 130, s. 2829–2837.
  - 50 Böll, B., et al.: Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSg) phase-I trial. *Br J Haematol*, 2019, 185, s. 42–52.
  - 51 Evens, A. M., et al.: Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): a detailed analysis from the phase 3 ECHELON-1 study. *Blood*, 2018, 132, suppl. 1, s. 1618–1618.
  - 52 Boell, B., et al.: B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSg) and the Nordic Lymphoma Group (NLG). *Blood*, 2018, 132, suppl. 1, s. 926–926.
  - 53 Eich, H. T., et al.: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol*, 2010, 28, s. 4199–4206.
  - 54 von Tresckow, B., et al.: Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. *J Clin Oncol*, 2012, 30, s. 907–913.
  - 55 André, M. P. E., et al.: Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol*, 2017, 35, s. 1786–1794.
  - 56 ChVP Therapy for Hodgkin's disease: Experience of 960 patients. *Ann Oncol*, 1995, 6, s. 167–172.
  - 57 Cullen, M. H., et al.: ChVP/PABIOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. *J Clin Oncol*, 1994, 12, s. 779–787.
  - 58 Specht, L., et al.: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). *Int J Radiat Oncol Biol Phys*, 2014, 89, s. 854–862.
  - 59 Evens, A. M., Carter, J., Loh, K. P., et al.: Management of older Hodgkin lymphoma patients. *Hematology Am Soc Hematol Educ Program*, 2019, 2019, s. 233–242.
  - 60 Pfreundschuh, M.: How I treat elderly patients with diffuse large B-cell lymphoma. *Blood*, 2010, 116, s. 5103–5110.
  - 61 Kolstad, A., et al.: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. *Leuk Lymphoma*, 2007, 48, s. 570–576.
  - 62 Fuchs, M., et al.: Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. *J Clin Oncol*, 2019, 37, s. 2835–2845.
  - 63 Engert, A., et al.: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med*, 2010, 363, s. 640–652.
  - 64 Younes, A., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.
  - 65 Younes, A., et al.: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med*, 2010, 363, s. 1812–1821.
  - 66 Chen, R., et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol*, 2017, 35, s. 2125–2132.
  - 67 Ansell, S. M.: Nivolumab in the treatment of Hodgkin lymphoma. *Clin Cancer Res*, 2017, 23, s. 1623–1626.
  - 68 Gopal, A. K., et al.: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. *Leuk Lymphoma*, 2014, 55, s. 2328–2334.
  - 69 Connors, J. M., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. *N Engl J Med*, 2018, 378, s. 331–344.
  - 70 Armand, P., et al.: Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol*, 2018, 36, s. 1428–1439.
  - 71 Ansell, S. M., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
  - 72 Herrera, A. F., et al.: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2018, 131, s. 1183–1194.
  - 73 Armand, P., et al.: KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. *Blood Adv*, 2020, 4, s. 2617–2622.
  - 74 Zinzani, P. L., et al.: Three-year follow-up of Keynote-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. *Blood*, 2019, 134, s. 240–240.
  - 75 Kuruvilla, J., et al.: Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol*, 2021, 22, s. 512–524.
  - 76 Lazarovici, J., et al.: Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa Phase II Study. *Blood*, 2021, 138, suppl. 1, s. 232.
  - 77 Cheson, B. D., et al.: Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. *Lancet Haematol*, 2020, 7, s. e808–e815.
  - 78 Yassenchak, C. A., et al.: Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged ≥ 60 years. *Blood*, 2019, 134, suppl. 1, s. 237.
  - 79 Allen, P., et al.: Frontline treatment with single agent pembrolizumab (PEM) followed by AVD chemotherapy for classic Hodgkin lymphoma: updated results and correlative analysis. *Blood*, 2021, 138, s. 231–231.
  - 80 Lee, H. J., et al.: Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary safety results from the single-arm phase II study (SGN35-027 Part B). *Blood*, 2021, 138, suppl. 1, s. 2454.
  - 81 Flinn, I., Friedman, J. D., Ho, L., et al.: Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced Hodgkin lymphoma (SGN35-027, TRIAL IN PROGRESS). *Hematol Oncol*, 2021, doi.org/10.1002/hon.160\_2880.
  - 82 Ramchandren, R., et al.: Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. *J Clin Oncol*, 2019, 37, s. 1997–2007.
  - 83 Bröckelmann, P. J., et al.: Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAH1 trial. *JAMA Oncol*, 2020, 6, s. 872–880.
  - 84 Younes, A., et al.: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
  - 85 Belada, D., Trněný, M., et al.: Diagnostické a léčebné postupy u nemocných s maligními lymfomy, 12. (online) doplněné vydání 2021. Dostupné z: www.lymphoma.cz.

## Současná terapie akutní lymfoblastické leukemie u dětí

doc. MUDr. Lucie Šrámková, Ph.D. Klinika dětské hematologie a onkologie, 2. LF UK a FN v Motole, Praha

- 1 Hunger, S. P., Mullighan, C. G.: Acute lymphoblastic leukemia in children. *N Engl J Med*, 2015, 373, s. 1541–1552.
- 2 Inaba, H., Mullighan, C. G.: Pediatric acute lymphoblastic leukemia. *Haematologica*, 2020, 105, s. 2524–2539.
- 3 Moorman, A. V.: New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. *Haematologica*, 2016, 101, s. 407–416.
- 4 Van Der Veer, A., Waanders, E., Pieters, R., et al.: Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. *Blood*, 2013, 122, s. 2622–2629.
- 5 Roberts, K. G., Li, Y., Payne-Turner, D., et al.: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med*, 2014, 371, s. 1005–1015.
- 6 Liu, Y., Easton, J., Shao, Y., et al.: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat Genet*, 2017, 49, s. 1211–1218.
- 7 Conter, V., Bartram, C. R., Valsecchi, M. G., et al.: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood*, 2010, 115, s. 3206–3214.
- 8 Schrappe, M., Valsecchi, M. G., Bartram, C. R., et al.: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood*, 2011, 118, s. 2077–2084.
- 9 Coustan-Smith, E., Gajjar, A., Hijjiya, N., et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. *Leukemia*, 2004, 18, s. 499–504.
- 10 Eckert, C., Biondi, A., Seeger, K., et al.: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. *Lancet*, 2001, 358, s. 1239–1241.
- 11 Raetz, E. A., Borowitz, M. J., Devidas, M., et al.: Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. *J Clin Oncol*, 2008, 26, s. 3971–3978.
- 12 Hagedorn, N., Acquaviva, C., Fronkova, E., et al.: Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: A more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee. *Blood*, 2007, 110, s. 4022–4029.
- 13 Krejci, O., van der Velden, V. H. J., Bader, P., et al.: Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: A report of the Pre-BMT MRD Study Group. *Bone Marrow Transplant*, 2003, 32, s. 849–851.
- 14 Lankester, A. C., Bierings, M. B., van Wering, E. R., et al.: Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. *Leukemia*, 2010, 24, s. 1462–1469.
- 15 Sramkova, L., Muzikova, K., Fronkova, E., et al.: Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*, 2007, 48, s. 93–100.
- 16 Pieters, R., De Lorenzo, P., Ancliffe, P., et al.: Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study. *J Clin Oncol Off J Am Soc Clin Oncol*, 2019, 37, s. 2246–2256.
- 17 Schultz, K. R., Carroll, A., Heerema, N. A., et al.: Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. *Leukemia*, 2014, 28, s. 1467–1471.
- 18 Hoffmann, P., Hofmeister, R., Brischwein, K., et al.: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19/CD3-bispecific single-chain antibody construct. *Int J Cancer*, 2005, 115, s. 98–104.
- 19 Dreier, T., Lorenczewski, G., Brandl, C., et al.: Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. *Int J Cancer*, 2002, 100, s. 690–697.
- 20 Löffler, A., Gruen, M., Wuchter, C., et al.: Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.

- Leukemia*, 2003, 17, s. 900–909.
- 21 Kantarjian, H. – Thomas, D. – Jorgensen, J., et al.: Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. *Lancet Oncol*, 2012, 13, s. 403–411.
  - 22 Bhowhani, D. – Sposto, R. – Shah, N. N., et al.: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Leukemia*, 2019, 33, s. 884–892.
  - 23 Maude, S. L. – Laetsch, T. W. – Buechner, J., et al.: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*, 2018, 378, s. 439–448.
  - 24 Park, J. H. – Rivière, I. – Gonen, M., et al.: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med*, 2018, 378, s. 449–459.
  - 25 Lee, D. W. – Kochenderfer, J. N. – Stetler-Stevenson, M., et al.: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. *Lancet*, 2015, 385, s. 517–528.
  - 26 Grupp, S. A. – Kalos, M. – Barrett, D., et al.: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med*, 2013, 368, s. 1509–1518.
  - 27 Maude, S. L. – Teachey, D. T. – Porter, D. L., et al.: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood*, 2015, 125, s. 4017–4023.
  - 28 Riegler, L. L. – Jones, G. P. – Lee, D. W.: Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. *Ther Clin Risk Manag*, 2019;15:323–335.
  - 29 Schmiegelow, K. – Attarbaschi, A. – Barzilai, S., et al.: Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. *Lancet Oncol*, 2016, 17, s. e231–e239.

## Chronická myeloidní leukemie – od poznání patogeneze k cílené léčbě onemocnění

doc. MUDr. Daniela Žáčková, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- 1 Bennett, J. H.: Case of hypertrophy of the spleen and liver in which death took place from supuration of the blood. *Edinb Med Surg J*, 1845, 64, s. 413–423.
- 2 Virchow, R.: Weisses Blut. *Frorieps Notizen*, 1845, 36, s. 151–156.
- 3 Geary, C. G.: The story of chronic myeloid leukaemia. *Br J Haematol*, 2000, 10, s. 2–11.
- 4 Nowell, P. C. – Hungerford, D. A.: A minute chromosome in human chronic granulocytic leukemia. *Science*, 1960, 132, s. 1497.
- 5 Rowley, J. D.: A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. *Nature*, 1973, 243, s. 290–293.
- 6 Daley, G. Q. – Van Etten, R. A. – Baltimore, D.: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. *Science*, 1990, 247, s. 824–830.
- 7 Druker, B. J. – Tamura, S. – Buchdunger, E., et al.: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. *Nat Med*, 1996, 2, s. 561–566.
- 8 Druker, B. J. – Talpaz, M. – Resta, D., et al.: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*, 2001, 344, s. 1031–1037.
- 9 Kantarjian, H. – Sawyers, C. – Hochhaus, A., et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Engl J Med*, 2002, 346, s. 645–652.
- 10 O'Brien, S. G. – Guilhot, F. – Larson, R. A., et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*, 2003, 348, s. 994–1004.
- 11 Hochhaus, A. – Larson, R. A. – Guilhot, F., et al.: Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *N Engl J Med*, 2017, 379, s. 917–927.
- 12 Gorre, M. E. – Mohammed, M. – Ellwood, K., et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*, 2001, 293, s. 876–880.
- 13 Kantarjian, H. M. – Giles, F. – Gattermann, N., et al.: Nilotinib (formerly AMN107), a highly effective selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood*, 2007, 110, s. 3540–3546.
- 14 Hochhaus, A. – Kantarjian, H. M. – Baccarani, M., et al.: Dasatinib induces no table hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood*, 2007, 109, s. 2303–2309.
- 15 Gambacorti-Passerini, C. – Brümmendorf, T. H. – Kim, D. W., et al.: Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. *Am J Hematol*, 2014, 89, s. 732–742.
- 16 Cortes, J. E. – Kim, D. W. – Pinilla-Ibarz, J., et al.: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med*, 2013, 369, s. 1783–1796.
- 17 Jian, Q. – Huand, X. – Chen, Z., et al.: Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic-and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP). *Blood*, 2020, 138, suppl. 1, s. 3598.
- 18 Rea, D. – Mauro, M. J. – Boquimpani, C., et al.: A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 prior TKIs. *Blood*, 2021, 138, s. 2031–2041.
- 19 Hochhaus, A. – Baccarani, M. – Silver, R. T., et al.: European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, 2020, 36, s. 966–984.
- 20 Jemal, A. – Siegel, R. – Xu, L., et al.: Cancer statistics 2010. *CA Cancer J Clin*, 2010, 60, s. 277–300.
- 21 Hehlmann, R.: How I treat CML blast crisis. *Blood*, 2012, 120, s. 737–747.
- 22 Hanfstein, B. – Müller, M. C. – Hehlmann, R., et al.: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia*, 2012, 26, s. 2096–2102.
- 23 Hehlmann, R. – Müller, M. C. – Lauseker, M., et al.: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. *J Clin Oncol*, 2014, 32, s. 415–423.
- 24 Steegmann, J. L. – Baccarani, M. – Breccia, M., et al.: European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*, 2016, 30, s. 1648–1671.
- 25 Hochhaus, A. – Saglio, G. – Hughes, T. P., et al.: Long-term benefits and risks of front end nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*, 2016, 30, s. 1044–1054.
- 26 Cortes, J. E. – Saglio, G. – Kantarjian, H. M., et al.: Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*, 2016, 34, s. 2333–2340.
- 27 Cortes, J. E. – Gambacorti-Passerini, C. – Deininger, M. W., et al.: Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. *J Clin Oncol*, 2018, 36, s. 231–237.
- 28 Quintás-Cardama, A. – Kantarjian, H. – O'Brien, S., et al.: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol*, 2007, 25, s. 3908–3914.
- 29 Cortes, J. E. – Kim, D. W. – Pinilla-Ibarz, J., et al.: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*, 2018, 132, s. 393–404.
- 30 Cortes, J. E. – Apperley, J. – Lomaia, E., et al.: Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. *Blood*, 2021, 138, s. 2042–2050.
- 31 Wylie, A. A. – Schoepfer, J. – Jahnke, W., et al.: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. *Nature*, 2017, 543, s. 733–737.
- 32 Cortes, J. E. – Hochhaus, A. – Takahashi, N., et al.: Trial in progress: a multicenter, open label, randomized, phase III study of asciminib (80 mg oncedaily) vs investigator-selected TKI in newly diagnosed adult patients with chronic myeloid leukemia in chronic phase. *Blood*, 2021, 138, suppl. 1, s. 1478.
- 33 Cortes, J. E. – Saikia, T. – Kim, D. W., et al.: An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobotinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lym. *Blood*, 2021, 138, suppl. 1, s. 309.
- 34 Hochhaus, A. – Saussele, S. – Baerlocher, G. M., et al.: Nilotinib vs nilotinib plus pegylated interferon-alpha2b induction and nilotinib or pegylated interferon-alpha2b maintenance therapy for newly diagnosed BCR-ABL+ chronic myeloid leukemia patients in chronic phase: interim analysis of the Tiger (CML V)-study. *Blood*, 2018, 132, suppl. 1, s. 460.
- 35 Mahon, F. X. – Réa, D. – Guilhot, J., et al.: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol*, 2010, 11, s. 1029–1035.
- 36 Rouselot, P. – Charbonnier, A. – Cony-Makhoul, P., et al.: Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. *J Clin Oncol*, 2014, 32, s. 424–430.
- 37 Saussele, S. – Richter, J. – Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. *Lancet Oncol*, 2018, 19, s. 747–757.
- 38 Radtisch, J. P. – Hochhaus, A. – Masszi, T., et al.: Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENEST freedom trial. *Leukemia*, 2021, 35, s. 1344–1355.
- 39 Shah, N. P. – García-Gutiérrez, V. – Jiménez-Velasco, A., et al.: Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. *Leuk Lymphoma*, 2020, 61, s. 650–659.
- 40 Rea, D. – Nicolini, F. E. – Tulliez, M., et al.: Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. *Blood*, 2017, 129, s. 846–854.
- 41 Richter, J. – Söderlund, S. – Lübking, A., et al.: Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? *J Clin Oncol*, 2014, 32, s. 2821–2823.
- 42 Clark, R. – Polydoros, F. – Apperley, J., et al.: De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. *Lancet Haematol*, 2019, 6, s. e375–e383.
- 43 Žáčková, D. – Faber, E. – Stejskal, L., et al.: Half: a prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. *Blood*, 2021, 138, s. 3606.

## Asciminib – tyrosinkinázový inhibitor s novým mechanismem účinku v léčbě chronické myeloidní leukemie – shrnutí aktuálních poznatků

MUDr. Lukáš Stejskal | MUDr. David Buffa Klinika hematologie, FN Ostrava a LF Ostravské univerzity, Ostrava-Poruba

MUDr. Zdeněk Kořístek, Ph.D. | prof. MUDr. Roman Hájek, CSc. Klinika hematologie, FN Ostrava, Klinika hematologie, LF Ostravské univerzity, Ostrava-Poruba

- 1 Hochhaus, A. – Baccarani, M. – Silver, R. T., et al.: European Leukemia-Net 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, 2020, 34, s. 966–984.
- 2 Hochhaus, A. – Sauselle, S. – Rosti, G., et al.: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv41–iv51.
- 3 Patel, A. B. – Wilds, B. W. – Deininger, M. W.: Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? *Expert Rev Hematol*, 2017, 10, s. 659–674.
- 4 Novartis Pharmaceuticals. Novartis receives FDA breakthrough therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia. Dostupné z: <https://www.>

- novartis.com/news/media-releases/novartis-receives-fda-break-through-therapy-designations-investigational-stamp-inhibitor-asciminib-abl001-chronic-myeloid-leukemia, vyhledáno 5. 8. 2022.
- FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. Dostupné z: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia>, vyhledáno 5. 8. 2022.
  - Schoepfer, J. – Jahnke, W. – Berellini, G., et al.: Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. *J Med Chem*, 2018, 61, s. 8120–8135.
  - Wylie, A. A. – Schoepfer, J. – Jahnke, W., et al.: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. *Nature*, 2017, 543, s. 733–737.
  - Lartigue, J. de: CML research aims to improve a „magic bullet“. *OncoLOGY Live*, 2020, 21.
  - Manley, P. W. – Barys, L. – Cowan-Jacob, S. W.: The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. *Leuk Res*, 2020, 98, s. 106458.
  - Eide, C. A. – Zabriskie, M. S. – Savage Stevens, S. L., et al.: Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. *Cancer Cell*, 2019, 36, s. 431–443.e5.
  - Hughes, T. P. – Mauro, M. J. – Cortes, J. E., et al.: Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. *N Engl J Med*, 2019, 381, s. 2315–2326.
  - Hughes, T.: Asciminib provides durable molecular responses in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. EHA Library. Hughes T. 06/10/22; 357566; P70.
  - Réa, D. – Mauro, M. J. – Boquimpani, C., et al.: A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. *Blood*, 2021, 138, s. 2031–2041.
  - Rea, D.: Efficacy and safety results from ASCSEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Wk 96 update, EHA Library. Rea D. 06/12/22; 357019; S155.
  - Yeung, D. T. – Shanmuganathan, N. – Hughes, T. P.: Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. *Blood*, 2022, 139, s. 3474–3479.
  - Hoch, M. – Sato, M. – Zack, J., et al.: Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. *J Clin Pharmacol*, 2021, 61, s. 1454–1465.
  - Study of efficacy of CML-CP patients treated with ABL001 versus bosutinib, previously treated with 2 or more TKIs. ClinicalTrials.gov Identifier: NCT03106779. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03106779>, vyhledáno 5. 8. 2022.
  - Databáze léků Státního ústavu pro kontrolu léčiv, Informace o specifickém léčebném programu. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0260427&tab=charges>, vyhledáno 5. 8. 2022.

## Možnosti současné farmakologické léčby hemofilie – přehledový článek

doc. MUDr. Zuzana Čermáková, Ph.D. | MUDr. Radomíra Hrdličková | MUDr. Šárka Blahutová

Krevní centrum FN a LF Ostravské univerzity, Ostrava

- Srivastava, A. – Brewer, A. K. – Mauser-Bunshoten, E. P., et al.: Guidelines for the management of hemophilia. *Haemophilia*, 2013, 19, s. e1–e47.
- Collins, P. W. – Blanchette, V. S. – Fischer, K., et al.: Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. *J Thromb Haemost*, 2009, 7, s. 413–420.
- Mahdi, A. J. – Obajji, S. G. – Collins, P. W.: Role of enhanced half-life factor VIII and IX of the haemophilia. *Br J Haematol*, 2015, 169, s. 768–776.
- Collins, P. W. – Young, G. – Knobe, K., et al.: Recombinant long-acting glykoPEGylated factor IX in haemophilia B: a multinational randomized phase 3 trial. *Blood*, 2014, 124, s. 3880–3886.
- Mahangu, J. – Powell, J. S. – Ragni, M. V., et al.: Phase study of recombinant factor VIII Fc fusion protein in hemophilia A. *Blood*, 2014, 123, s. 317–325.
- Graf, L.: Extended half-life factor VIII and FIX preparations. *Transf Med*, 2018, 45, s. 86–91.
- SPC Adynovi. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi>, vyhledáno 14. 8. 2022.
- SPC Jivi. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/jivi>, vyhledáno 14. 8. 2022.
- SPC Esperoct. Dostupné z: [https://www.ema.europa.eu/en/documents/product-information/esperoct-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/esperoct-epar-product-information_en.pdf), vyhledáno 14. 8. 2022.
- Konkle, B. A. – Shapiro, A. – Quon, D., et al.: BIV001 fusion protein as factor VIII replacement therapy for hemophilia A. *N Engl J Med*, 2020, 383, s. 1018–1027.
- Key, N. S.: Inhibitors in congenital coagulation disorders. *Br J Haematol*, 2004, 127, s. 379–391.
- Lambert, T. – Benson, G. – Dolan, G., et al.: Practical aspects of extended half-life products for the treatment of haemophilia. *Ther Adv Hematol*, 2018, 9, s. 295–308.
- Lenting, P. J. – Denis, C. V. – Christophe, O. D.: Eimicizumab, a bispecific antibody recognizing coagulation factors IX and X; how does it compare to factor VIII? *Blood*, 2017, 130, s. 2463–2468.
- Mahangu, J. N. – Blanchette, V. – Klamroth, R.: Redefining prophylaxis in the modern era. *Haemophilia*, 2020, <https://doi.org/10.1111/hae.14035>.
- Marchesini, E. – Morfini, M. – Valentino, L.: Recent advances in the treatment of hemophilia: review. *Biologics*, 2021, 15, s. 221–235.
- Valentino, L. A. – Khair, K.: Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. *Expert Rev Hematol*, 2020, 13, s. 731–743.
- ISTH 2022. Dostupné z: <https://www.isth2022.org/abstracts>, vyhledáno 14. 8. 2022.
- Mancuso, E. M. – Mahangu, J. N. – Pipe, S. W.: The changing treatment landscape in hemophilia: from standards half-life clotting factors concentrates to gene editing. *Lancet*, 2021, 397, s. 630–640.

## Současné možnosti léčby hluboké žilní trombózy v onkologii, budoucí možné výhledy

doc. MUDr. Jana Hirmerová, Ph.D. II. interní klinika LF UK a FN Plzeň

- Horsted, F. – West, J. – Grainge, M. J.: Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *PLoS Med*, 2012, 9, s. e1001275.
- Key, N. S. – Kasthuri, R. S.: Current treatment of venous thromboembolism. *Arterioscler Thromb Vasc Biol*, 2010, 30, s. 372–375.
- Charalel, R. A. – Vedantham, S.: Deep vein thrombosis interventions in cancer patients. *Semin Intervent Radiol*, 2017, 34, s. 50–53.
- Lee, A. Y. – Levine, M. N. – Baker, R. I., et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med*, 2003, 349, s. 146–153.
- Raskob, G. E. – van Es, N. – Verhamme, P., et al.: Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med*, 2018, 378, s. 615–624.
- Young, A. M. – Marshall, A. – Thirlwall, J., et al.: Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol*, 2018, 36, s. 2017–2023.
- McBane, R. D. 2nd – Wysokinski, W. E. – Le-Rademacher, J. G., et al.: Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost*, 2020, 18, s. 411–421.
- Agnelli, G. – Becattini, C. – Meyer, G.: Apixaban for the treatment of venous thromboembolism associated with cancer. *N Engl J Med*, 2020, 382, s. 1599–1607.
- Kearon, C. – Akl, E. A. – Ornelas, J., et al.: Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*, 2016, 149, s. 315–352.
- Key, N. S. – Khorana, A. A. – Kuderer, N. M., et al.: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*, 2020, 38, s. 496–520.
- Lyman, G. H. – Carrier, M. – Ay, C., et al.: American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*, 2021, 5, s. 927–974.
- Stevens, S. M. – Woller, S. C. – Kreuziger, L. B., et al.: Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. *Chest*, 2021, 160, s. e545–e608.
- Farge, D. – Frere, C. – Connors, J. M., et al.: 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. *Lancet Oncol*, 2022, 23, s. e334–e347.
- Samuelson Bannow, B. T. – Lee, A. – Khorana, A. A., et al.: Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. *J Thromb Haemost*, 2018, 16, s. 1246–1249.
- Moik, F. – Pabinger, I. – Ay, C.: How I treat cancer-associated thrombosis. *ESMO Open*, 2020, 5, s. e000610.
- Srivastava, P. – Gailani, D.: The rebirth of the contact pathway: a new therapeutic target. *Curr Opin Hematol*, 2020, 27, s. 311–319.
- [www.sukl.cz](http://www.sukl.cz).